AI-09 In Subjects With Glabellar Lines, GL-101

August 26, 2025 updated by: Eirion Therapeutics Inc.

A Phase 1/2 Study to Establish An Initial Therapeutic Range and Safety Data for AI-09 in the Treatment of Glabellar Lines

AI-09 In Subjects with Glabellar Lines

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

A Phase 1/2, multicenter, out-patient, prospectively randomized, double-blind, vehicle-controlled study to establish an initial therapeutic range for AI-09 in the treatment of glabellar lines and provide initial data regarding its potential safety.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
72

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • Florida
      • Boca Raton, Florida, United States, 33432
        • Eirion Research Site
      • Miami, Florida, United States, 33137
        • Eirion Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

16 years to 66 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • able to understand and give written informed consent
  • willingness to have their pictures taken
  • 20 - 70 years of age
  • moderate to severe glabellar lines (IGA 2-3) on contraction
  • moderate to severe glabellar lines (SSA 2-3) on contraction
  • none to mild glabellar lines wrinkles (IGA 0-1) at rest
  • willingness to refrain from the use of facial fillers, retinoids, Botox, laser treatments, or any product affecting skin remodeling or that might cause an active dermal response during the course of the study
  • female subjects of child-bearing potential must have a negative urine pregnancy test and be non-lactating at the Baseline visit
  • female subjects of child-bearing potential must utilize one of the following methods of birth control throughout the study: IUD, diaphragm, a condom, a spermicidal gel or foam, oral contraceptives (provided subject has been utilizing this method for at least 4 months prior to Baseline and has not changed the brand within this period), or patch, injectable, implantable, or vaginal ring contraceptives. Subjects may also participate if they are surgically sterilized (tubal sterilization or hysterectomy)
  • subjects should be in good general health as determined by the investigator and free of any disease that may interfere with study evaluations or the Investigational Product

Exclusion Criteria:

  • the inability to substantially lessen glabellar lines by physically spreading them apart
  • excessive weakness or atrophy in the target muscle(s)
  • eyelid ptosis
  • presence or history of "dry eye"
  • history of periocular surgery, brow lift or related procedures, or deep dermal scarring
  • concurrent or recent (within the last 6 months) use of any other botulinum toxin drug product anywhere in the body
  • history of immunization or hypersensitivity to any botulinum toxin serotype
  • history of non-response to any prior botulinum toxin treatments
  • anticipated need for treatment with botulinum toxin of any serotype for a reason during the trial (other than the investigational treatment)
  • any medical condition that may put the subject at increased risk with exposure to botulinum toxin including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
  • pregnancy or lactation
  • application of any topical prescription medication to the treatment area within 14 days prior to treatment
  • subjects on clinically significant, concomitant drug therapy
  • participation in another investigational drug trial or receiving any investigational treatment(s) within 30 days of Baseline
  • alcohol or drug abuse within the past 3 years
  • psychiatric disease interfering with the subject's ability to give informed consent
  • refusal or inability to comply with the requirements of the protocol for any reason

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: AI-09 Dose 1
Dose 1 of botulinum toxin, Type A, intramuscular injection, administered once at baseline
Biological: AI-09
Botulinum toxin, Type A, intramuscular injection, administered once at baseline
Placebo Comparator: Vehicle Dose 1
Vehicle, intramuscular injection, administered once at baseline
Biological: Vehicle
Vehicle Formulation
Experimental: AI-09 Dose 2
Dose 2 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
Biological: AI-09
Botulinum toxin, Type A, intramuscular injection, administered once at baseline
Placebo Comparator: Vehicle Dose 2
Vehicle, intramuscular injection, administered once at baseline
Biological: Vehicle
Vehicle Formulation
Experimental: AI-09 Dose 3
Dose 3 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
Biological: AI-09
Botulinum toxin, Type A, intramuscular injection, administered once at baseline
Placebo Comparator: Vehicle Dose 3
Vehicle, intramuscular injection, administered once at baseline
Biological: Vehicle
Vehicle Formulation
Experimental: AI-09 Dose 4
Dose 4 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
Biological: AI-09
Botulinum toxin, Type A, intramuscular injection, administered once at baseline
Placebo Comparator: Vehicle Dose 4
Vehicle, intramuscular injection, administered once at baseline
Biological: Vehicle
Vehicle Formulation
Experimental: AI-09 Dose 5
Dose 5 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
Biological: AI-09
Botulinum toxin, Type A, intramuscular injection, administered once at baseline
Placebo Comparator: Vehicle Dose 5
Vehicle, intramuscular injection, administered once at baseline
Biological: Vehicle
Vehicle Formulation
Experimental: AI-09 Dose 6
Dose 6 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
Biological: AI-09
Botulinum toxin, Type A, intramuscular injection, administered once at baseline
Placebo Comparator: Vehicle Dose 6
Vehicle, intramuscular injection, administered once at baseline
Biological: Vehicle
Vehicle Formulation
Experimental: AI-09 Dose 7
Dose 7 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
Biological: AI-09
Botulinum toxin, Type A, intramuscular injection, administered once at baseline
Placebo Comparator: Vehicle Dose 7
Vehicle, intramuscular injection, administered once at baseline
Biological: Vehicle
Vehicle Formulation

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Investigators Global Assessment (IGA)
Time Frame: 18 Weeks (26 Weeks for Cohorts 4, 5 & 6)
Investigators Global Assessment. Glabellar Line Severity scale where severity is scored between 0-4 (0=absent; 4=severe).
18 Weeks (26 Weeks for Cohorts 4, 5 & 6)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Total Number of Observations With a Response Defined as Change ≥2 in IGA-C and SSA-C Score
Time Frame: Week 1, 2, 4, 8, 12, 18 (Week 26 assessments for Cohorts 4, 5 & 6)
Total number of observations with a change in the Investigators Global Assessment on Contraction, IGA-C, and the Subject Self-Assessment on Contraction, SSA-C, using the Glabellar Line Severity scale (GLS), where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as a change by at least two ordinals in both assessments.
Week 1, 2, 4, 8, 12, 18 (Week 26 assessments for Cohorts 4, 5 & 6)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Eirion Therapeutics Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 3, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 3, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 3, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 27, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 3, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 4, 2022

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 27, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 26, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • AI-09-GL-101

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glabellar Frown Lines

Clinical Trials on Vehicle

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings